The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of a low-emetic combination of S-1 plus docetaxel (DTX) for advanced non-small cell lung cancer (NSCLC).
K. Komiyama
No relevant relationships to disclose
K. Kobayashi
No relevant relationships to disclose
S. Minezaki
No relevant relationships to disclose
Y. Uchida
No relevant relationships to disclose
T. Kasai
No relevant relationships to disclose
K. Mori
No relevant relationships to disclose
E. Hoshi
No relevant relationships to disclose
S. Koyama
No relevant relationships to disclose
K. Eguchi
No relevant relationships to disclose
M. Nakayama
No relevant relationships to disclose
K. Kikuchi
No relevant relationships to disclose